Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference36 articles.
1. Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87.
2. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–70.
3. Fundación SER. Se ha presentado el Estudio EPISER 2016 en la sede del Ministerio de Sanidad, Consumo y Bienestar Social-SER. 2019. https://www.ser.es/se-ha-presentado-el-estudio-episer-2016-en-la-sede-del-ministerio-de-sanidad-consumo-y-bienestar-social/. Accessed 29 Jan 2020.
4. Cabrera-Salom C, Motta Beltrán A, Medina Y. Presentación inusual de psoriasis ostrácea y artritis psoriásica: resultados después de 10 años de manejo con infliximab. Revis Colomb Reumatol. 2019. https://www.elsevier.es/es-revista-revista-colombiana-reumatologia-374-pdf-S0121812318300367. Accessed 29 Jan 2020.
5. Coates L, Gossec L. The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences. Jt Bone Spine. 2023;90(1):105469.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献